Stefan Grass
No más puestos en curso
Fortuna: 63 537 $ al 30/04/2024
Historial de carrera de Stefan Grass
Antiguos cargos conocidos de Stefan Grass.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
CSL Behring AB
 CSL Behring AB Pharmaceuticals: MajorHealth Technology CSL Behring AB develops, manufactures, and markets protein-based therapies in the bleeding disorders, critical care, immunoglobulins, and pulmonary areas. It offers therapies such as plasma-derived and recombinant coagulation factors, immunoglobulins for the treatment of primary immune deficiency, alpha1-proteinase inhibitor for chronic A1-PI augmentation therapy, and C1-INH concentrate. The company was founded in 1904 and is headquartered in Danderyd, Sweden. | Corporate Officer/Principal | - | - |
| BACTIGUARD HOLDING AB | Director Técnico/Científico/I+D | 31/10/2019 | - |
Formación de Stefan Grass.
| Karolinska Institutet | Doctorate Degree |
Estadísticas
Internacional
| Suecia | 4 |
Operativa
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| BACTIGUARD HOLDING AB | Health Technology |
| Empresas privadas | 1 |
|---|---|
CSL Behring AB
CSL Behring AB Pharmaceuticals: MajorHealth Technology CSL Behring AB develops, manufactures, and markets protein-based therapies in the bleeding disorders, critical care, immunoglobulins, and pulmonary areas. It offers therapies such as plasma-derived and recombinant coagulation factors, immunoglobulins for the treatment of primary immune deficiency, alpha1-proteinase inhibitor for chronic A1-PI augmentation therapy, and C1-INH concentrate. The company was founded in 1904 and is headquartered in Danderyd, Sweden. | Health Technology |
- Bolsa de valores
- Insiders
- Stefan Grass
- Experiencia
